{rfName}
Mu

Indexed in

License and use

Citations

Altmetrics

Analysis of institutional authors

Sune, GuillermoAuthor
Share
Publications
>
Abstract

Multiplex CRISPR/Cas9 Genome Editing of Cord Blood-derived CAR NK Cells to Improve Their Persistence and Antitumoral Potential Against Multiple Myeloma

Publicated to:Clinical Lymphoma Myeloma & Leukemia. 24 S1-S2 - 2024-09-01 24(), DOI:

Authors: Castellano, E; García-Ortiz, A; Maroto-Martin, E; Encinas, J; Oliva, R; Alvarez, N; Carreñno, G; Ayala, R; Córdoba, L; Leivas, A; Fernández, RA; Cedena, MT; Río, P; Valeri, A; Ugalde, L; García-García, L; Suñé, G; Martín-Antonio, B; Martínez-Lopez, J

Affiliations

Biomed Res Ctr rare Dis netwotk CIBERER, Madrid, Spain - Author
CIBERONC, Madrid, Spain - Author
Clin Barcelona Hosp, IDIBAPS, Barcelona, Spain - Author
Complutense Univ, Hosp 12 Octubre, Dept Hematol, Barcelona, Spain - Author
Ctr Invest Energet Medioambientales & Tecn, Madrid, Spain - Author
Fdn Jimenez Diaz Res Inst, Dept Expt Hematol, Barcelona, Spain - Author
H12O CNIO Clin Res Unit, Madrid, Spain - Author
Hosp 12 Octubre imas12, Inst Invest Sanitaria Hosp, Madrid, Spain - Author
Hosp Univ 12 Octubre, Ctr Nacl Invest Oncol H12OCNIO, Madrid, Spain - Author
ICMHO, Dept Hematol, Barcelona, Spain - Author
UAM, Fdn Jimenez Diaz Res Inst IIS FJD, Madrid, Spain - Author
Univ Complutense UCM, Madrid, Spain - Author
See more

Abstract

Keywords
BiotecnologíaCancer researchCiências biológicas iHematologyMedicina iMedicina iiOncology

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Clinical Lymphoma Myeloma & Leukemia due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 163/322, thus managing to position itself as a Q2 (Segundo Cuartil), in the category Oncology. Notably, the journal is positioned en el Cuartil Q3 para la agencia Scopus (SJR) en la categoría Hematology.